<DOC>
	<DOCNO>NCT00291889</DOCNO>
	<brief_summary>Vaccination tuberculosis ( TB ) /healthy PPD-negative adult age 18 45 years.Three dos primary vaccination follow booster dose completion primary vaccination course . Booster vaccination give subject receive candidate tuberculosis vaccine subject receive active comparators control .</brief_summary>
	<brief_title>Safety Immunogenicity GSK Biological 's Candidate Tuberculosis Vaccine Mtb72F/AS02 Healthy PPD-negative Adults .</brief_title>
	<detailed_description>The safety immunogenicity 2 antigen dos PPD-negative adult evaluate . In addition , 2 active comparator group volunteer receive vaccine alone without immunostimulant 1 control group receive adjuvant ( AS02 ) alone assess true effect candidate tuberculosis vaccine ( Mtb72F/AS02 ) .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>INCLUSION CRITERIA : Written inform consent Healthy PPDnegative volunteer age 18 45 year No evidence pulmonary pathology ( i.e . acute chronic pulmonary disease ; past TB infection/disease ) confirm chest Xray . Seronegative HIV 1 2 , HBsAg , HCV Clinically normal laboratory value creatinine , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin , complete blood count ( CBC ) differential , haemoglobin , platelet count urinalysis . Females : Non pregnant , must use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . EXCLUSION CRITERIA : Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month prior first vaccine dose . History prior Bacillus CalmetteGu√©rin ( BCG ) vaccination . History document exposure Mycobacterium tuberculosis History prior vaccination experimental Mycobacterium Tuberculosis vaccine experimental product contain MPL QS21 . Any confirm suspected immunosuppressive immunodeficient condition ; family history congenital hereditary immunodeficiency . History hypersensitivity vaccine vaccine component History acute chronic illness medication , opinion investigator , may interfere evaluation safety immunogenicity vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>